A leading healthcare venture capital firm with multiple offices in USA invests in transformative biotechnology, medical technology, and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. The firm invests in both privately held and publicly traded companies through a variety of investment approaches.
The firm has raised nearly $2 billion in capital commitments and is investing from a fourth core fund of $585 million. The firm makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. The firm primarily invests in North America and Europe but may also consider opportunities in the Middle East.
The firm invests in biotechnology, medical technology, diagnostics, healthcare services, and healthcare IT. The firm is generally agnostic regarding indications. The firm invests across a range of stages, from development through profitability, but prefers to back technologies that have attained proof of concept data.
The firm invests in both pre-revenue companies and post-revenue companies. The firm typically leads or co-leads investments, and prefers to take a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply